Natural history of Hurler syndrome (MPS I-H)
The natural history of Hurler syndrome (MPS I-H) describes how the disease progresses over time, both without treatment and in the era of haematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT). Before these treatments were available, Hurler syndrome was almost always fatal in early childhood. Modern therapies have transformed survival and neurocognitive outcomes for many children, but significant long term disease burden remains, especially in the skeleton, heart and airways.
This page summarises what long term studies and registry data show about disease course, life expectancy and quality of life in Hurler syndrome, with a focus on severe MPS I-H.
Disease Course Over Time
Hurler syndrome before HSCT and ERT
In the pre-treatment era, children with Hurler syndrome typically appeared well at birth. Subtle signs, such as hernias, frequent infections and emerging coarse facial features, became apparent during the first year of life. Over the next few years, they developed progressive skeletal deformities, joint stiffness, hepatosplenomegaly, cardiac valve disease, airway obstruction and worsening developmental delay.
Historical cohorts from specialist centres and registry data show that, without HSCT or ERT:
- Developmental milestones initially progress slowly, then plateau and regress between 2 and 4 years of age.
- Most children develop severe intellectual disability, loss of speech and loss of independent mobility.
- Recurrent chest infections, obstructive sleep apnoea, heart failure and spinal cord compression are common.
- The majority of untreated children die between 5 and 10 years of age, most often from respiratory or cardiac complications.
These observations established Hurler syndrome as a rapidly progressive, life limiting neurodegenerative disease in early childhood.
How HSCT and ERT have changed outcomes
The introduction of haematopoietic stem cell transplantation (HSCT) in the early 1980s, and later enzyme replacement therapy (ERT) with laronidase, has significantly altered the natural history of severe MPS I-H. HSCT aims to provide a permanent source of donor-derived cells that secrete functional alpha L iduronidase, while ERT supplies recombinant enzyme systemically.
Survival & Treatment
HSCT performed in the first 2 to 2.5 years of life improves survival compared with historical untreated cohorts.
Many transplanted children retain useful language and cognitive abilities into later childhood, particularly when transplanted at a young age and with good donor chimerism.
Neurocognitive Outcomes
ERT given before and after HSCT reduces GAG levels, improves endurance and supports cardiorespiratory function, especially in the peri-transplant period.
HSCT plus ERT has changed Hurler syndrome from a uniformly fatal condition in early childhood to a chronic, multisystem disorder with survival into adolescence and adulthood for many patients.
Survival in children transplanted for Hurler syndrome
Large series of children transplanted for Hurler syndrome report overall survival rates in the range of **70–90 percent at 5 to 10 years after HSCT** in experienced centres, with best outcomes in those transplanted early and with matched donors. Some cohorts now include survivors into their 20s and 30s.
Key factors associated with better survival include:- Younger age at transplant (ideally before 2 years of age)
- Good donor match and sustained donor chimerism
- Lower burden of cardiorespiratory disease at the time of transplant
- Care in specialised metabolic and transplant centres
Despite these improvements, HSCT still carries significant risks, including graft failure, graft versus host disease and transplant related mortality. These risks must be balanced against the severe natural history of untreated Hurler syndrome.
Survival Comparison
Brain and development after early HSCT
One of the main goals of early HSCT in Hurler syndrome is to preserve neurocognitive function. Long term studies show that:
- Children transplanted very early, often before 18–24 months of age and before significant developmental decline, can maintain IQ scores in or near the low-normal range and attend mainstream or supported schooling.
- Children transplanted later, or with more advanced neurological involvement at baseline, are more likely to have moderate or severe intellectual disability, despite HSCT.
- Even in the best cases, subtle learning difficulties, problems with attention, processing speed and executive function are common.
These data emphasise the importance of early diagnosis, including newborn screening, and rapid referral for transplant assessment in infants with severe MPS I-H.
Developmental Trajectory Over Time
Life with Hurler syndrome in the modern era
As survival has improved, more children with Hurler syndrome are reaching adolescence and adulthood. Studies using health-related quality of life tools show that many transplanted individuals and their families report better overall health and participation than would be expected in untreated Hurler syndrome, but still face substantial challenges.
Examples include:
- Need for repeated hospitalisations and surgeries (orthopaedic, ENT, cardiac)
- Limitations in mobility and physical activities
- Chronic pain, fatigue and sleep problems
- Impact of hearing or vision impairment on education and work
- Emotional and social challenges, including anxiety about future health
Quality of life is influenced by disease severity, timing of treatment, family and social support, and access to specialist care.
“Many young people and adults who underwent HSCT in early childhood attend school or college, participate in adapted sports and social activities, and develop meaningful roles in family and community life.”
— Long term quality of life studies
ERT in the natural history of severe and attenuated MPS I
In attenuated MPS I, long term studies show that ERT alone can improve endurance, reduce liver and spleen size, improve lung function and stabilise or slow progression of cardiac and skeletal disease. For severe MPS I-H, ERT is mainly used as an adjunct to HSCT rather than a standalone therapy, because it does not cross the blood–brain barrier effectively and cannot prevent the neurocognitive decline that characterises untreated Hurler syndrome.
Key points:
- In severe MPS I-H, ERT is generally not sufficient on its own to alter long term neurodevelopmental outcome.
- ERT is valuable in the peri-transplant period and in patients who are not HSCT candidates, helping to reduce GAG load and support organ function.
- Long term ERT may maintain or improve some somatic features, but skeletal and cardiac disease often progress over time.
Why understanding natural history still matters
Even in the era of HSCT and ERT, the natural history of untreated or partially treated Hurler syndrome remains important. It provides the baseline against which the benefits and limitations of current therapies are measured and helps to:
Justify early and intensive treatment in infants with severe MPS I-H.
Explain to families why, despite treatment, some complications still occur.
Design clinical trials and choose meaningful outcome measures for new therapies, including gene and cell-based approaches.
Support health-economic analyses, policy decisions and newborn screening programmes.
A clear understanding of natural history is also essential for regulatory agencies when evaluating new treatments, because it provides the context for assessing long term benefit and risk.
Future directions informed by natural history
The experience of the past four decades shows that HSCT and ERT have changed Hurler syndrome from an invariably fatal early childhood disease to a chronic condition with extended survival but ongoing morbidity. This "treated natural history" highlights residual needs in brain and airway disease and natural needs the development of brain and therapies, such as systemic gene therapy, gene-modified stem cell transplantation and targeted delivery platforms designed to reach the central nervous system and skeleton more effectively.
Any new therapy must be compared not just with untreated historical cohorts, but with the outcomes of children treated early with HSCT and optimised supportive care. Long term follow up and registries will remain critical to understand whether these new strategies truly change the life course of Hurler syndrome.
Learn more about research and future therapies →Evolution of Treatments
Key points about natural history in Hurler syndrome
- Without HSCT or ERT, Hurler syndrome leads to rapid neurocognitive decline and death, usually in early childhood.
- Early HSCT, often combined with ERT, improves survival and preserves cognitive function in many children, especially when performed before significant developmental decline.
- Even after successful HSCT, many patients have lifelong skeletal, cardiac, airway, hearing and vision complications.
- Quality of life in survivors is highly variable, but many children and adults can participate in education, work and social activities with appropriate support.
- Understanding natural history helps families make informed decisions about treatment and helps researchers design and evaluate new therapies.
Every child with Hurler syndrome is unique. Statistics and cohort data provide useful guidance, but your child’s outlook depends on many factors. Your metabolic and transplant team can give you the most accurate information for your own situation.